Indian Pharma Exports to US Fell 10% Last Year
Diversification into new global markets is reshaping trade strategies for pharmaceutical exporters.
Updated on Sept. 18, 2026 in Healthcare
Live Poll
Is diversifying export markets away from a single dominant partner beneficial for national economic stability?
India's pharmaceutical exports to the United States declined by nearly 10 percent last year, representing a loss of approximately USD 1 billion in value. Historically, the U.S. market accounted for 35 percent of India's total pharmaceutical exports.
Why it matters
To mitigate the impact of reduced demand in the U.S., Indian exporters are actively diversifying their reach toward Brazil, Latin America, Africa, and Europe. This shift marks a strategic pivot away from heavy reliance on a single primary market.
Indian pharmaceutical exports to the U.S. fell to USD 9.5 billion last year, down from USD 10.5 billion previously. Despite this, total industry exports rose 6.8 percent to USD 8.1 billion in the April-June 2026 quarter compared to USD 7.5 billion in the same period of 2025.
The players
Pharmexcil
The state-sponsored export promotion council responsible for organizing international health expos and coordinating trade strategy for Indian pharmaceutical manufacturers.
The details
Industry leaders are consolidating the promotion of pharmaceuticals, medical devices, and nutraceuticals to maintain growth. By leveraging regional exhibitions like the Bharat Health Global Expo, the sector aims to stabilize its supply chain and reduce dependency on the American market. This diversification strategy is intended to insulate manufacturers from volatility in any single national market.
Timeline
Last year, exports to the United States declined by nearly 10 percent.
During the April-June 2026 quarter, total pharmaceutical exports increased by 6.8 percent.
The second Bharat Health Global Expo is scheduled for 2027.
Market Landscape
This decline reflects a broader recalibration of India's trade strategy, moving away from high-concentration dependency. The current pivot aligns with the Indian Ministry of Commerce and Industry's export diversification initiatives to spread market risk.
Operators managing supply chains dependent on Indian pharmaceuticals should anticipate shifting trade routes and potentially higher procurement complexity as volumes divert to other regions. It is essential to monitor regional trade agreements in Africa and Brazil as these markets increasingly absorb supply previously destined for the U.S.
The takeaway
The sharp decline in U.S.-bound exports serves as a reminder of the risks inherent in single-market trade dependency. Business operators should audit their current supplier concentration and track quarterly export growth reports to identify potential supply chain vulnerabilities.
What happens next
The second edition of the Bharat Health Global Expo is planned for 2027 to continue the push into non-U.S. markets.
Further reading
For more on international sector shifts, visit the Healthcare section.
Live Poll
Is diversifying export markets away from a single dominant partner beneficial for national economic stability?
